Is LXRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

956 people get LXRX articles and Market Currents by email alert.

Get email alerts on LXRX »

HEADLINES:

Lexicon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)
Thu, May 16
Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference

PR Newswire (May 13, 2013)
Lexicon Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10 • 2 Comments
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial

PR Newswire (May 10, 2013)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results

PR Newswire (May 10, 2013)
Lexicon to Report First Quarter Financial Results on May 10, 2013

PR Newswire (May 3, 2013)
No News Becoming Bad News For Lexicon Pharmaceuticals
Stephen Simpson • Tue, Apr 30 • 10 Comments
Lexicon To Present At The Needham Healthcare Conference

PR Newswire (Apr 25, 2013)
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
Lexicon To Present At The Cowen Healthcare Conference

PR Newswire (Mar 1, 2013)
Lexicon To Present At The RBC Capital Markets Healthcare Conference

PR Newswire (Feb 25, 2013)
Lexicon Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 21 • 2 Comments
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results

PR Newswire (Feb 21, 2013)
Lexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013

PR Newswire (Feb 18, 2013)
Lexicon To Present At The BIO CEO & Investor Conference

PR Newswire (Feb 6, 2013)
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Will 2013 Be A Better Year For Zalicus?
C.R. Jackson • Thu, Jan 10 • 2 Comments
Lexicon Pharmaceuticals' Management Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)
Wed, Jan 9
Investors Wait On Developments For Lexicon Pharmaceuticals
Brian L. Wilson • Thu, Jan 3 • 12 Comments
Lexicon To Present At The J.P. Morgan Healthcare Conference

PR Newswire (Jan 3, 2013)

No News Becoming Bad News For Lexicon Pharmaceuticals
Stephen Simpson • Tue, Apr 30 • 10 Comments

No News Becoming Bad News For Lexicon Pharmaceuticals
Stephen Simpson • Tue, Apr 30 • 10 Comments
Investors Wait On Developments For Lexicon Pharmaceuticals
Brian L. Wilson • Thu, Jan 3 • 12 Comments
Lexicon Pushes On To Phase III
Stephen Simpson • Fri, Oct 12, 2012 • 8 Comments
Clinical Trial Data Spikes Lexicon Pharma Shares
Brian L. Wilson • Fri, Oct 12, 2012
Lexicon Needs Differentiated Data To Drive Deals And Value
Stephen Simpson • Mon, Aug 6, 2012 • 11 Comments
Is Lexicon Right For Your Long-Term Speculative Holdings?
Rx Stocks • Mon, Jul 9, 2012 • 3 Comments
FDA Rejection Of Dapaglifozin Means Little For Lexicon
Stephen Simpson • Fri, Jan 20, 2012 • 7 Comments
Lexicon Pharmaceuticals: A Worthwhile Speculation
Stephen Simpson • Thu, Jan 5, 2012 • 2 Comments
Lexicon Pharmaceuticals: Stuck in Phase II?
VFC's Stock House • Wed, Nov 11, 2009 • 2 Comments

Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
How Individuals Can Gain An Advantage Over Institutional Investors
Robert Mann • Tue, Jan 29 • 5 Comments
Will 2013 Be A Better Year For Zalicus?
C.R. Jackson • Thu, Jan 10 • 2 Comments
3 Compelling Biopharma Stocks For 2013
EnhydrisPECorp • Wed, Dec 26, 2012 • 4 Comments
3 Small Pharma Companies With Major Catalysts In 2013
Chemistfrog • Mon, Dec 17, 2012 • 6 Comments
Top 5 Stocks With Insider Buys Filed During The Week Ending October 26
Markus Aarnio • Sun, Oct 28, 2012
Biotech Weekend Recap: Clinical Trials, Company Files
Brian L. Wilson • Sun, Oct 14, 2012 • 6 Comments
7 Small Cap Stocks Holding Low Debt Ratios And Positive Analyst Ratings
ZetaKap • Tue, Aug 21, 2012
Tuesday's Top Biotech Chart: iBio Inc.
James Stocklasar Thomas Jr. • Tue, Jul 24, 2012 • 41 Comments
Why Early Tuesday's Biotech Edge Is Bullish
James Stocklasar Thomas Jr. • Tue, Jul 17, 2012 • 17 Comments
Get In Early Monday On These Biotech Favorites
James Stocklasar Thomas Jr. • Mon, Jul 16, 2012 • 30 Comments
Small-Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Thu, Jul 12, 2012 • 5 Comments
7 Highly Liquid Stocks Under $5 On Winning Streaks
Kapitall • Wed, Jul 4, 2012 • 3 Comments
3 Rising Biotech Stars All Under $2/Share
James Stocklasar Thomas Jr. • Mon, Jun 18, 2012 • 17 Comments
10 Rallying Stocks Under $5 Being Bought Up By Hedge Funds
Kapitall • Sun, Jun 17, 2012 • 1 Comment
10 Rallying Biotech Stocks Being Snapped Up By Hedge Funds
Kapitall • Tue, Jun 12, 2012 • 1 Comment
Wednesday's Bio Pharma Drug Approval And Catalyst Watch List
Scott Matusow • Wed, May 2, 2012 • 15 Comments
10 Value Stocks Under $2
Furbonacci • Sun, Apr 15, 2012 • 8 Comments
Noteworthy Institutional 5% Ownership Filings This Week In Healthcare Sector
GuruFundPicks • Wed, Apr 11, 2012
18 Stocks Under $5 Being Bought Up By Hedge Funds
Kapitall • Mon, Apr 2, 2012 • 2 Comments

Lexicon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript)
Thu, May 16
Lexicon Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10 • 2 Comments
Lexicon Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 21 • 2 Comments
Lexicon Pharmaceuticals' Management Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)
Wed, Jan 9
Lexicon Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Nov 6, 2012
Lexicon Pharmaceuticals' CEO Presents at Morgan Stanley Global Healthcare Conference (Transcript)
Tue, Sep 11, 2012
Lexicon's CEO Presents at Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)
Tue, Aug 14, 2012
Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 31, 2012
Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data from Phase 2b Trial (Transcript)
Tue, Jun 26, 2012
Lexicon Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, May 3, 2012
Lexicon Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 22, 2012
Lexicon Pharmaceuticals' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Wed, Jan 11, 2012 • 2 Comments
Lexicon Pharmaceuticals' CEO Discusses Q3 2011 Results - Earnings Call Transcript
Tue, Nov 1, 2011
Lexicon Pharmaceuticals' CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Aug 9, 2011
Lexicon Pharmaceuticals' CEO Discusses Q1 2011 Results - Earnings Call Transcript
Tue, May 3, 2011 • 1 Comment
Lexicon Pharmaceuticals, Inc. CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 24, 2011
Lexicon Pharmaceuticals CEO Discusses Q3 2010 Results – Earnings Call Transcript
Fri, Nov 5, 2010
Lexicon Pharmaceuticals Incorporated Q2 2010 Earnings Call Transcript
Mon, Aug 9, 2010
Lexicon Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Thu, May 13, 2010
Lexicon Pharmaceuticals, Inc. Q4 2009 Earnings Call Transcript
Tue, Feb 23, 2010

Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference

PR Newswire (May 13, 2013)
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial

PR Newswire (May 10, 2013)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results

PR Newswire (May 10, 2013)
Lexicon to Report First Quarter Financial Results on May 10, 2013

PR Newswire (May 3, 2013)
Lexicon To Present At The Needham Healthcare Conference

PR Newswire (Apr 25, 2013)
Lexicon To Present At The Cowen Healthcare Conference

PR Newswire (Mar 1, 2013)
Lexicon To Present At The RBC Capital Markets Healthcare Conference

PR Newswire (Feb 25, 2013)
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results

PR Newswire (Feb 21, 2013)
Lexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013

PR Newswire (Feb 18, 2013)
Lexicon To Present At The BIO CEO & Investor Conference

PR Newswire (Feb 6, 2013)
Lexicon To Present At The J.P. Morgan Healthcare Conference

PR Newswire (Jan 3, 2013)
Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA

PR Newswire (Dec 17, 2012)
Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference

PR Newswire (Nov 20, 2012)
Lexicon Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference

PR Newswire (Nov 12, 2012)
LX4211 Phase 2b Results Presented At American Heart Association Annual Conference

PR Newswire (Nov 6, 2012)
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results

PR Newswire (Nov 6, 2012)
Lexicon to Provide Third Quarter 2012 Financial Results

PR Newswire (Oct 31, 2012)
Lexicon Announces Pricing Of Common Stock Offering

PR Newswire (Oct 18, 2012)
Lexicon Announces Proposed Common Stock Offering

PR Newswire (Oct 17, 2012)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Oct 12, 2012)

LXRX vs. ETF Alternatives

Company Description

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. We have used our proprietary gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 7:07 AM Lexicon Pharmaceuticals (LXRX) reports progressing into the placebo-controlled portion of its Phase 2 trial of LX4211 in patients with type 1 diabetes. No partnership deal is announced, meaning - for now - the company is going it alone as testing moves forward. (earnings earlier) (PR) Comment! [Healthcare]
Friday, May 10, 6:10 AM Lexicon Pharmaceuticals (LXRX): Q1 EPS of -$0.05 in-line. Revenue of $400K beats by $100K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 29, 12:56 PM Midday top 10 gainers: OSH +43%. WRLS +31%. CPTS + 19%. MDSO +20%. GALT +19%. LEDS +18%. FXEN +17%. OSBC +14%. PRGN +12%. CCH +12%.
Midday top 10 losers: LAS -31%. NTE -28%. HGSH -20%. GWAY -19%. LXRX -18%. FVE -15%. AUXL -11%. MLP -10%. CETV -10%. BIOL -10%. Comment! [On the Move]
Thursday, February 21, 6:09 AM Lexicon Pharmaceuticals (LXRX): Q4 EPS of -$0.05 in-line. Revenue of $218K misses by $150K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, December 31, 2012, 2:27 PM Lexicon Pharmaceuticals (LXRX +15.4%) moves up today on no company-specific news. The company earned fast track status earlier this month from the FDA for its LX1033 drug candidate, an orally delivered small molecule medication for irritable bowel syndrome with diarrhea. Comment! [Healthcare, On the Move]
Monday, December 31, 2012, 12:45 PM Midday top 10 gainers: UNXL +22%. AMRS +21%. DUF +20%. PTEK +17%. FFNM +17%. LXRX +15%.FORD +15%. ALJ +15%. PMFG +12%. EXE +12%.
Midday top 10 Losers: EMITF -13%. CFBK -12%. MARK -10%. CALM -10%. DLIA -10%. BIOF -9%.LTBR -9%. GRH -9%. WSBF -8%.FSI -8%. Comment! [On the Move]
Monday, December 31, 2012, 9:10 AM Premarket gainers: LXRX +7%.
Comment! [On the Move]
Monday, December 17, 2012, 1:53 PM Lexicon Pharmaceuticals (LXRX +8%) gets a pop today after earlier saying it's received fast track status from the FDA for LX1033, its orally-delivered drug candidate for diarrhea-predominant irritable bowel syndrome. The drug inhibits the reaction of tryptophan hydroxylase in the gastrointestinal tract, and is currently being evaluated in Phase II clinical trials. Comment! [Healthcare, On the Move]
Monday, December 17, 2012, 9:10 AM Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
Losers: NBG -13%. CLWR -11%. SQNM -6%. Comment! [On the Move]
Monday, December 17, 2012, 9:06 AM Lexicon Pharma (LXRX) +8.5% premarket after its LX1033 drug candidate for irritable bowel syndrome receives fast track status from the FDA. Comment! [Healthcare, On the Move]
Tuesday, November 6, 2012, 5:02 PM Shares of Lexicon Pharmaceuticals (LXRX) finished -4% today, despite its earlier announcement that that favorable data from Phase 2b clinical trials of its diabetes drug LX4211 was being presented today at the American Heart Association Scientific Sessions Conference in Los Angeles. According to the company, results demonstrate potential benefits in improving glycemic control, as well as reductions in cardiovascular risk factors such as blood pressure and body weight. Comment! [Healthcare, On the Move]
Thursday, October 18, 2012, 12:45 PM Midday top 10 gainers: CYBI +81%. OEH +26%. BWEN +23%. IESC +20%. ETH +20%. GIVN +18%. AEGR +17%. VIMC +16%. WCC +14%. CHCI +13.
Top 10 Losers: ALGN -24%. MNKD -23%. MLNX -21%. CYTR -19%. GORO -16%. IMUC -14%. RCON -13%. LXRX -11%. BCOM -11%. UFPI -11%. Comment! [On the Move]
Thursday, October 18, 2012, 10:18 AM Lexicon (LXRX -10.8% to $2.23) sinks sharply after pricing an offering of 17.5M shares at $2.25 each, a 10% discount to yesterday's close. The net proceeds will be $37.2M, which the biotech plans to use for R&D. The underwriters have an option to purchase another 2.625M shares. (PR) 2 Comments [Healthcare, On the Move]
Thursday, October 18, 2012, 9:10 AM Premarket gainers: GIVN +13%. WCC +11%. SVU +9%. JNPR +7%. NVAX +7%. MGM +6%. AEGR +5%.
Losers: MNKD -25%. CYTR -20%. ALGN -20%. IMUC -18%. LXRX -16%. MLNX -15%. GORO -14%. CDR -7%. SCSS -7%. VRNG -6%. 1 Comment [On the Move]
Friday, October 12, 2012, 12:45 PM Midday top 10 gainers: NINE +62%. CRMB +16%. NPSP +15%. AEGR +13%. GLUU +12%. LXRX +11%. TSON +11%. BIOF +10%. EMAN +10%. BSDM +9%.
Top 10 Losers: AEZS -24%. OCZ -17%. TZOO -14%. PURE -11%. INVE -11%. AMD -10%. LQDT -10%. CCCL -9%. INFY -9%. Comment! [On the Move]
Friday, October 12, 2012, 8:33 AM Lexicon Pharmaceuticals (LXRX) +12.5% premarket after revealing positive top-line results from a midstage study for telotristat etiprate, its investigational new drug to treat carcinoid syndrome. The drug currently has fast track status and orphan drug designation from the FDA, and orphan drug designation from European regulators. Comment! [Healthcare, On the Move]

IALF
$LXRX looks to be down due to $MRK and $PFE deal. Time to find a new bottom.
Apr 29, 10:49 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sford834
Lexicon Pharmaceuticals ($LXRX) still offers good value at the current level. Market cap at $1.11B, most recent closing price at $2.16.
Apr 25, 3:25 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sford834
$LXRX has offered an average of 43.8% Return on Equity over the past 3 years.
Apr 25, 3:22 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/cCUM Premarket loser $ALGN (-19%), $MLNX(-15%), $LXRX(-11%), $CLWR(-6%), $IRM(-14%), $USG (-7%)
10/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Master Che
Stock updates: HAL HPQ HRL KO KMP LINE LINTA LNKD LXRX MCD MRK NCT NFLX NTAP http://bit.ly/Nz9iQD
10/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Master Che
Stock updates: GE GIS GOOG GMCR HAL HPQ HRL INTC KO KMP LINE LINTA LNKD LXRX MCD MSFT -http://bit.ly/Nz9iQD
10/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

IALF
LXRX pulling back still - looking to start a new position. Anyone think it will drop to 2.20 range again?
9/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Small Cap Stocks Holding Low Debt Ratios And Positive Analyst Ratings http://bit.ly/RzDpZA $APOG $CCC $DVAX $ESGR $KNX $LXRX $SMCI
8/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Clark
NEW TRADING SHORT POSITIONS: AONEQ.PK, ARNA, BMI, LXRX, OREX http://seekingalpha.com/p/j3xv
7/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/LKa5tc Premarket gainer $LXRX, $ALXA, $QSFT, $SQQQ, $TSLA, $STZ, $ACT, $STJ, $VXX $TVIX $UVXY
6/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Winning Will
LXRX at 1.50 looks like a good spot to get in! Outstanding pipeline with one of their development drugs being fast tracked by the FDA!
5/1/12
Reply (1)

• !Report Abuse
View all 1 replies
Winning Will: Wish I didn't Sell @ 2.00... Saw this one coming just didn't think it would double so quickly
7/16/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
http://bit.ly/ItRIdu LXRX Receives funding for phase II Clinical trial of their drug for type 1 diabetes!
5/3/12
Reply (2)

• !Report Abuse
View all 2 replies
Winning Will: keep up the momentum! LXRX looking good early on
5/3/12
• !Report Abuse
Winning Will: Roller coaster day for LXRX but looking good coming into the home stretch. Big 5% gain on a bad overall market
5/3/12
• !Report Abuse
Add a reply...

140 characters

LXRX Lexicon Pharmaceuticals, Inc.

LXRX

Lexicon Pharmaceuticals, Inc.